Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandrine Faivre

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
The Lancet. Oncology|July 10, 2009
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II studySandrine Faivre, Eric Raymond, Eveline Boucher, et al.
Neuroendocrinology|March 9, 2018
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine NeoplasmsAnna Pellat, Chantal Dreyer, Camille Couffignal, et al.
British Journal of Cancer|April 7, 2021
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpressionThomas Decaens, Carlo Barone, Eric Assenat, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2025
Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II TrialLouis Gros, Mohamed Bouattour, Clément Dumont, et al.
Oncotarget|August 11, 2016
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinibMaria Serova, Annemilaï Tijeras-Raballand, Celia Dos Santos, et al.
Cancers|September 23, 2022
Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA StudyDiane Evrard, Clément Dumont, Michel Gatineau, et al.
Targeted Oncology|November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid TumorsJean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skinEve Maubec, Peter Petrow, Isabelle Scheer-Senyarich, et al.
The Lancet. Oncology|June 11, 2013
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialJan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, et al.
Targeted Oncology|November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation TrialCéleste Lebbé, Antoine Italiano, Nadine Houédé, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
The Lancet. Oncology|July 10, 2009
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II studySandrine Faivre, Eric Raymond, Eveline Boucher, et al.
Neuroendocrinology|March 9, 2018
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine NeoplasmsAnna Pellat, Chantal Dreyer, Camille Couffignal, et al.
British Journal of Cancer|April 7, 2021
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpressionThomas Decaens, Carlo Barone, Eric Assenat, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2025
Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II TrialLouis Gros, Mohamed Bouattour, Clément Dumont, et al.
Oncotarget|August 11, 2016
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinibMaria Serova, Annemilaï Tijeras-Raballand, Celia Dos Santos, et al.
Cancers|September 23, 2022
Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA StudyDiane Evrard, Clément Dumont, Michel Gatineau, et al.
Targeted Oncology|November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid TumorsJean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skinEve Maubec, Peter Petrow, Isabelle Scheer-Senyarich, et al.
The Lancet. Oncology|June 11, 2013
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialJan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, et al.
Targeted Oncology|November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation TrialCéleste Lebbé, Antoine Italiano, Nadine Houédé, et al.
Pageof 14